Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COI-B regimen as first-line therapy for metastatic colorectal cancer
2008-008749-39Phase 2Completed
- Sponsor
- ITMO University
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, capecitabine, irinotecan and oxaliplatin in colorectal cancer (CRC), sponsored by ITMO University. Primary endpoints: Response rate, Safety profile of the COI regimen with bevacizumab and 1 more. Started Mar 2009; status: completed.
02
Drugs
bevacizumabcapecitabineirinotecanoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-008749-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008749-39.